BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8045917)

  • 21. Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II.
    Kahán Z; Sun B; Schally AV; Arencibia JM; Cai RZ; Groot K; Halmos G
    Cancer; 2000 Mar; 88(6):1384-92. PubMed ID: 10717621
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of growth of MDA-MB-231 human breast cancer xenografts in nude mice by bombesin/gastrin-releasing peptide (GRP) antagonists RC-3940-II and RC-3095.
    Miyazaki M; Lamharzi N; Schally AV; Halmos G; Szepeshazi K; Groot K; Cai RZ
    Eur J Cancer; 1998 Apr; 34(5):710-7. PubMed ID: 9713279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatostatin analog RC-160 and bombesin/gastrin-releasing peptide antagonist RC-3095 inhibit the growth of androgen-independent DU-145 human prostate cancer line in nude mice.
    Pinski J; Halmos G; Schally AV
    Cancer Lett; 1993 Jul; 71(1-3):189-96. PubMed ID: 8103419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Powerful inhibition of in-vivo growth of experimental hepatic cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
    Szepeshazi K; Schally AV; Rick FG; Block NL; Vidaurre I; Halmos G; Szalontay L
    Anticancer Drugs; 2012 Oct; 23(9):906-13. PubMed ID: 22926257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bombesin antagonists inhibit growth of MDA-MB-435 estrogen-independent breast cancers and decrease the expression of the ErbB-2/HER-2 oncoprotein and c-jun and c-fos oncogenes.
    Bajo AM; Schally AV; Krupa M; Hebert F; Groot K; Szepeshazi K
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3836-41. PubMed ID: 11891317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of growth of PC-82 human prostate cancer line xenografts in nude mice by bombesin antagonist RC-3095 or combination of agonist [D-Trp6]-luteinizing hormone-releasing hormone and somatostatin analog RC-160.
    Milovanovic SR; Radulovic S; Groot K; Schally AV
    Prostate; 1992; 20(4):269-80. PubMed ID: 1376910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers.
    Rick FG; Buchholz S; Schally AV; Szalontay L; Krishan A; Datz C; Stadlmayr A; Aigner E; Perez R; Seitz S; Block NL; Hohla F
    Cell Cycle; 2012 Jul; 11(13):2518-25. PubMed ID: 22751419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix.
    Chatzistamou I; Schally AV; Szepeshazi K; Groot K; Hebert F; Arencibia JM
    Cancer Lett; 2001 Sep; 171(1):37-45. PubMed ID: 11485826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095.
    Szepeshazi K; Schally AV; Halmos G; Groot K; Radulovic S
    J Natl Cancer Inst; 1992 Dec; 84(24):1915-22. PubMed ID: 1460673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers.
    Bajo AM; Schally AV; Groot K; Szepeshazi K
    Br J Cancer; 2004 Jan; 90(1):245-52. PubMed ID: 14710236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A potent bombesin receptor antagonist inhibits bombesin-stimulated growth of mouse colon cancer cells in vitro: absence of autocrine effects.
    Narayan S; Spindel ER; Rubin NH; Singh P
    Cell Growth Differ; 1992 Feb; 3(2):111-8. PubMed ID: 1323998
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bombesin receptors in a human duodenal tumor cell line: binding properties and function.
    Williams BY; Schonbrunn A
    Cancer Res; 1994 Feb; 54(3):818-24. PubMed ID: 8306345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific binding and growth effects of bombesin-related peptides on mouse colon cancer cells in vitro.
    Narayan S; Guo YS; Townsend CM; Singh P
    Cancer Res; 1990 Nov; 50(21):6772-8. PubMed ID: 2208141
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The binding of bombesin and somatostatin and their analogs to human colon cancers.
    Radulovic SS; Milovanovic SR; Cai RZ; Schally AV
    Proc Soc Exp Biol Med; 1992 Jul; 200(3):394-401. PubMed ID: 1352046
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GRP-preferring bombesin receptors increase generation of inositol phosphates and tension in rat myometrium.
    Amiot F; Leiber D; Marc S; Harbon S
    Am J Physiol; 1993 Dec; 265(6 Pt 1):C1579-87. PubMed ID: 8279518
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
    Kanashiro CA; Schally AV; Groot K; Armatis P; Bernardino AL; Varga JL
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15836-41. PubMed ID: 14660794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.